Transurethrale Injektionen mit Bulkamid

 

 Buy Article Permissions and Reprints

Zusammenfassung

Das Bulkamid-Bulking-Verfahren ist gering invasiv und bietet sich als Alternative zur Behandlung der Belastungsinkontinenz unter anderem für Patientinnen mit Adipositas, Komorbiditäten und Rezidiven nach anderen Eingriffen an. Am DRK Krankenhaus Chemnitz-Rabenstein haben wir seit Oktober 2005 247 Patientinnen mit Bulkamid behandelt. Die Erfolgsrate liegt bei 67,9 % und 47,5 % der Patientinnen sind objektiv geheilt, was insbesondere in Anbetracht der Negativauswahl der Patientinnen in Bezug auf Alter, BMI, Komorbidität und Rezidiven nach anderen Verfahren ein positives Ergebnis ist. 80,1 % der Patientinnen sind mit dem Resultat zufrieden und die Erfolgsrate ist zwischen 6 und 30 Monaten nach dem Eingriff unverändert. Das Material bietet gute Eigenschaften. Die Vorteile der Injektionsbehandlung liegen in der einfachen Durchführbarkeit und niedrigen Komplikationsrate. Der Eingriff ist von den Patientinnen gut akzeptiert und aus Anwendersicht leicht erlernbar. Zur endgültigen Bewertung sind jedoch weitere Daten erforderlich.

Abstract

Due to its minimally invasive character, Bulkamid bulking may be an alternative procedure for the treatment of female urinary stress incontinence in patients with adipositas, comorbidities or relapse after other treatments. At the DRK Clinic Chemnitz-Rabenstein we have treated 247 women with Bulkamid since October 2005. The success rate was 67.9 % with 47.5 % of the patients objectively cured. This constitutes a positive result, particularly when considering the problematic selection criteria such as age, BMI, comorbidities and relapse following other treatments. 80.1 % of the patients are happy with the result and there was no notable change in the post treatment success rate at 6 and 30 months. The material has good properties, with ease of use, visual control and low complication rates constituting the key advantages of this approach. It is well accepted by patients and easy for the operating surgeon to learn, although more data are needed for a final evaluation.

Literatur

• 1 Beutel M E, Hessel A, Schwarz R et al. Prevalence of urinary incontinence in the German population. Prävalenz der Urininkontinenz in der deutschen Bevölkerung. Komorbidität, Lebensqualität, Einflussgrössen.  Der Urologe [A]. 2005;  44 232-238
  CrossrefPubMedGoogle Scholar
• 2 Welz-Barth A, Füsgen I, Melchior H J. 1999 rerun of the 1996 German Urinary Incontinence Survey: Will doctors ever ask?.  World J Urol. 2000;  18 436-438
  CrossrefPubMedGoogle Scholar
• 3 Distler W. Harninkontinenz – Tabuthema in der Postmenopause.  Zae FQ. 2000;  94 211-215
  PubMedGoogle Scholar
• 4 Papanicolaou S, Pons M E, Hampel C et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study.  Maturitas. 2005;  52 (Suppl. 2) S35-S47
  PubMedGoogle Scholar
• 5 Stamey T A. Endoscopic suspension of the vesical neck for surgically curable urinary incontinence in the female.  Monogr Urol. 1981;  2 65
  PubMedGoogle Scholar
• 6 Klarskov N, Lose G. Urethral injection therapy: what is the mechanism of action?.  Neurourol Urodyn. 2008;  27 789-792
  CrossrefPubMedGoogle Scholar
• 7 Klarskov N, Lose G. Urethral pressure reflectometry and pressure profilometry in healthy volunteers and stress urinary incontinent women.  Neurourol Urodyn. 2008;  27 807-812
  CrossrefPubMedGoogle Scholar
• 8 Sander P, Lose G. Surgical options in the treatment of stress urinary incontinence in women (Review).  Minerva Ginecol. 2007;  59 619-627
  PubMedGoogle Scholar
• 9 Klarskov N, Lose G. Urethral pressure reflectometry vs. urethral pressure profilometry in women: a comparative study of reproducibility and accuracy.  BJU Int. 2007;  100 351-356
  CrossrefPubMedGoogle Scholar
• 10 Lose G, Mouritsen L, Nielsen J B. A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women.  BJU Int. 2006;  98 100-104
  CrossrefPubMedGoogle Scholar
• 11 Hunskaar S, Lose G, Sykes D et al. The prevalence of urinary incontinence in women in four European countries.  BJU Int. 2004;  93 324-330
  CrossrefPubMedGoogle Scholar
• 12 Sørensen C, Sander P, Lose G. Experiences with bulkamid at Glostrup-Hospital.  Int Urogynecol J. 2007;  18 (Suppl. 1) S190-S191
  PubMedGoogle Scholar
• 13 Appell R A, Dmochowski R R, Herschorn S. Urethral injections for female stress incontinence.  BJU Int. 2006;  98 (Suppl. 1) 27-30
  CrossrefPubMedGoogle Scholar
• 14 Balmforth J, Cardozo L D. Trends toward less invasive treatment of female stress urinary incontinence.  Urology. 2003;  62 52-60
  CrossrefPubMedGoogle Scholar
• 15 Cody J, Wyness L, Wallace S et al. Systematic review of the clinical effectiveness and cost-effectiveness of tension-free vaginal tape for treatment of urinary stress incontinence.  Health Technol Assess. 2003;  7 22
  PubMedGoogle Scholar
• 16 Iselin C E, Webster G D. Office management of female urinary incontinence.  Urogynecol. 1998;  25 625
  PubMedGoogle Scholar
• 17 Keegan P E, Atiemo K, Cody J et al. Periurethral injection therapy for urinary incontinence in women.  Cochrane Database Syst Rev. 2007; 
  PubMedGoogle Scholar
• 18 Lightner D J. Review of the available urethral bulking agents.  Curr Opin Urol. 2002;  12 333-338
  CrossrefPubMedGoogle Scholar
• 19 Lightner D J, Itano N B, Sweat S D et al. Injectable agents: present and future.  Curr Urol Rep. 2002;  3 408-413
  CrossrefPubMedGoogle Scholar
• 20 Pannek J, Brands F H, Senge T. Particle migration after transurethral injection of carbon coated beads for stress urinary incontinence.  J Urol. 2001;  166 1350-1353
  CrossrefPubMedGoogle Scholar
• 21 Perimenis P, Giannitsas K. Injectables for the treatment of stress urinary incontinence: current use and future perspectives.  Expert Opin Pharmacother. 2006;  7 1441-1447
  CrossrefPubMedGoogle Scholar
• 22 Starkman J S, Scarpero H, Dmochowski R R. Emerging periurethral bulking agents for female stress urinary incontinence: is new necessarily better?.  Curr Urol Rep. 2006;  7 405-413
  CrossrefPubMedGoogle Scholar
• 23 Su T H, Hsu C Y, Chen J C. Injection therapy for stress incontinence in women.  Int Urogynecol J Pelvic Floor Dysfunct. 1999;  10 200-206
  CrossrefPubMedGoogle Scholar
• 24 Sweat S D, Lightner D J. Complications of sterile abscess formation and pulmonary embolism following periurethral bulking agents.  J Urol. 1999;  161 93-96
  CrossrefPubMedGoogle Scholar
• 25 Kerr L A. Bulking agents in the treatment of stress urinary incontinence: history, outcomes, patient populations and reimbursement profile.  Rev Urol. 2005;  7 (Suppl. 1) S3-S11
  PubMedGoogle Scholar
• 26 Smith E A, Oehme F W. Acrylamide and polyacrylamide: a review of production, use, environmental fate and neurotoxocity.  Rev Environ Health. 1991;  9 215-228
  PubMedGoogle Scholar
• 27 King D J, Noss R R. Toxicity of polyacrylamide and acrylamide monomer.  Rev Environ Health. 1989;  8 3-16
  PubMedGoogle Scholar
• 28 Guaraldi G, Orlando G, De Fazio D et al. Comparison of three different interventions for the correction of HIV-associated facial lipoatrophy: a prospective study.  Antiviral Ther. 2005;  10 753-759
  PubMedGoogle Scholar
• 29 Lose G, Mouritsen L, Nielsen J B. A new bulking agent (polyacrylamide hydrogel) for treating stress urinary incontinence in women.  BJU Int. 2006;  98 100-117
  CrossrefPubMedGoogle Scholar
• 30 Bello G, Jackson I T, Keskin M, Kelly C et al. The use of polyacrylamide gel in soft-tissue augmentation: an experimental assessment.  Plast Reconstr Surg. 2007;  119 1326-1336
  CrossrefPubMedGoogle Scholar
• 31 Lightner D J. Review of the available urethral bulking agents.  Curr Opin Urol. 2002;  12 333-338
  CrossrefPubMedGoogle Scholar
• 32 Schultz J A, Nager C W, Stanton S L, Baessler K. Bulking agents for stress urinary incontinence: short-term results and complications in a randomized comparison of periurethral and transurethral injections.  Int Urogynecol J Pelvis Floor Dysfunct. 2004;  15 261-265
  PubMedGoogle Scholar
• 33 Qiao Q, Wang X, Sun J, Zhao R et al. Management for postoperative complications of breast augmentation by injected poly-acrylamide hydrogel.  Aesth Plast Surg. 2005;  29 156-161
  CrossrefPubMedGoogle Scholar
• 34 Cheng N, Xu S, Deng H et al. Migration of implants: a problem with injectable polyacrylamide gel in aesthetic plastic surgery.  Aesth Plast Surg. 2006;  30 215-225
  CrossrefPubMedGoogle Scholar
• 35 von Buelow S, von Heimburg D, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation.  Plast Reconstr Surg. 2005;  116 1137-1146 discussion 1147-1148
  PubMedGoogle Scholar
• 36 von Buelow S, Pallua N. Efficacy and safety of polyacrylamide hydrogel for facial soft-tissue augmentation in a 2-year follow-up: a prospective multicenter study for evaluation of safety and aesthetic results in 101 patients.  Plast Reconstr Surg. 2006;  118 (Suppl. 3) 85S-91S
  CrossrefPubMedGoogle Scholar
• 37 Lise H C. Tissue integration of polyacrylamide hydrogel: an experimental study of periurethral, perivesical, and mammary gland tissue in the pig.  Dermatol Surg. 2008;  34 S68-S77
  CrossrefPubMedGoogle Scholar
• 38 Appel R, Dmochowski R, Herschorn S. Optimum attributes for ideal bulking agent.  BJU International. 2006;  98 (Suppl. 1) 27-30
  CrossrefPubMedGoogle Scholar

Dr. med. Kurt Lobodasch

DRK Krankenhaus Chemnitz-Rabenstein
Frauenklinik

Unritzstraße 23

09117 Chemnitz

Email: lobodasch@drk-chemnitz.de